Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Q2 Profit Declines 15 Percent on 2.5-Percent Revenue Growth

This article has been updated to correct the change in PerkinElmer's net income, which declined to $24.5 million, not by $24.5 million.

NEW YORK (GenomeWeb News) – PerkinElmer today said second-quarter net income declined 15 percent as revenues inched up 2.5 percent.
 
Receipts for the three months ended July 2 increased to $377 million from $368 million year over year.
 
Revenue from the Life and Analytical Sciences segment increased 3 percent to $278.5 million from $270.8 million year over year. The genetic screening and service businesses contributed to the increase, the company said in a statement.
 
Revenue for the Optoelectronics segment remained essentially flat, at $98.5 million compared to $97 million from the same period last year.
 
R&D costs increased 13 percent to $25 million from $22 million from the comparable quarter a year ago.
 
PerkinElmer also reported a decline in net income to $24.5 million for the second quarter compared to $29 million last year.
 
PerkinElmer had $324 million in cash and cash equivalents as of July 2.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.